

LIFE SCIENCE CONFERENCE

DEVELOPMENT OF TOXICOLOGY/ ECOTOXICOLOGY
NEW REGULATIONS, NEW BUSINESS OPPORTUNITIES

On January 26, 2010
at the Salk Institute San Diego

PROVENCE PROMOTION
CONTACT / Matthieu Vis
+ 33 (0)4 96 11 60 25
m.vis@provence-promotion.fr

Featured Provence Companies



Founded in 2007, **SIGENTEC** is a contract research organisation providing industries with a wide range of in vitro assays in toxicology for the development of new products and for compliance with the REACH legislation. The know-how of **SIGENTEC** enables to evaluate safety and efficacy of compounds in several sectors including the cosmetic and chemical industries.

Laetitia MATEO earned a Ph.D. in Microbiology and Molecular Biotechnology from the University of Marseille. She worked on the protection of DNA in human epidermal cells against physical injury such as UV or oxidative stress. She also studied the potentially toxic effects of metallic nanoparticles. She is specialised in genotoxicology and in the development of new toxicological in vitro assays. Willing to put her expertise in toxicology at the disposal of industrial, she co-founded SIGENTEC in 2007 and serves as chief executive officer.



A CRO and biomarker solutions provider, **BIOVAYS** boasts unique savoir-faire in the localisation and quantification of biomarkers. Harnessing next generation cellular & tissular imaging technologies and proprietary software tools,

BIOVAYS offers a wide range of in vitro and ex vivo models for research and development studies in a number of sectors including the cosmetics, pharmaceutical and food-processing industries.

Stéphane LUCCHINI has a scientific research background, acquiring a PhD in Neurobiology. Fuelled by a desire to explore new horizons, he co-founded a CRO in the year 2000 performing in vivo studies for the pharmaceutical industry. In 2007 he joined BIOVAYS as Business Manager in charge of structuring the then fledgling company and developing its service portfolio: biomarker solutions for research and development projects.



ICDD is the first company to offer a toxicity test leveraging the full potential of the mitochondria. Founded in 2007 by renown scientists, **ICDD** is an innovative company developing solutions to improve safety and efficacy of drugs as early as possible in the development process. As of

today, **ICDD** is offering a full range of tests: **Mitosafe®** for early deselection of hits, **Mitostream®** for anticipation of lead/candidate clinical tolerance, and **Mitoselect®** to determine the best efficacy/toxicity balance in neurodegenerative diseases.

Nathalie COMPAGNONE holds a Ph.D in Developmental Neuroscience and pursued an academic career until 2004, when she directed a research laboratory in the Neurosurgery department at UCSF. At this date, she gained a double competence in bio-entrepreneurship (CBE, UCSF) and accepted a position in the pharmaceutical industry to head the development of drug for Huntington disease at Trophos. Combining both experiences, she founded ICDD with three other European scientists to commercialize solutions bypassing toxicity bottlenecks in the process of drug development. Nathalie is the co-inventor in several patents including that of the Mitostream® platform operated by ICDD.